Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. (Delaware) reports on a Special Meeting of Stockholders held on November 13, 2019. The company is classified as an emerging growth company. The filing details the results of three specific proposals submitted to shareholders for approval regarding the company's capital structure.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance actions and voting results rather than financial performance metrics.
Material Changes and Voting Results
Shareholders approved three significant amendments to the Company's Certificate of Incorporation:
- Authorized Share Increase: The number of authorized common shares was increased from 150,000,000 to 300,000,000.
- For: 18,725,236
- Against: 4,752,389
- Abstentions: 11,141
- Reverse Stock Split Authorization: The Board was authorized to effect a reverse stock split at a ratio between 1-for-2 and 1-for-100, with discretion on the exact ratio and whether to proceed. This revises a proposal approved on May 30, 2019.
- For: 19,930,132
- Against: 3,549,088
- Abstentions: 9,546
- Authorized Share Reduction: The Board was authorized to reduce the number of authorized shares in proportion to the decrease in outstanding shares resulting from the reverse split.
- For: 20,106,670
- Against: 3,332,717
- Abstentions: 49,379
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the implications of the approved corporate actions. The primary contingency noted is the Board's discretion to determine the exact ratio of the reverse stock split or to decide not to effect the split at all.
Investor Verification Checklist
- Verify the exact reverse stock split ratio and implementation date, as the Board retains discretion within the 1-for-2 to 1-for-100 range.
- Confirm the updated total number of authorized shares (300,000,000) in subsequent filings.
- Monitor for any future reduction in authorized shares if the reverse split is executed.
- Review the company's financial statements (e.g., 10-K or 10-Q) for liquidity and operational metrics, as they are not included in this 8-K.